Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617

Mostrar otras versiones (1)

COVID-19 pathogen SARS-CoV-2 has infected hundreds of millions and caused over 5 million deaths to date. Although multiple vaccines are available, breakthrough infections occur especially by emerging variants. Effective therapeutic options such as monoclonal antibodies (mAbs) are still critical. Her...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Lei, Hu, Yingxia, Mankowski, Madeleine C., Ren, Ping, Chen, Rita E., Wei, Jin, Zhao, Min, Li, Tongqing, Tripler, Therese, Ye, Lupeng, Chow, Ryan D., Fang, Zhenhao, Wu, Chunxiang, Dong, Matthew B., Cook, Matthew, Wang, Guilin, Clark, Paul, Nelson, Bryce, Klein, Daryl, Sutton, Richard, Diamond, Michael S., Wilen, Craig B., Xiong, Yong, Chen, Sidi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960874/
https://www.ncbi.nlm.nih.gov/pubmed/35347138
http://dx.doi.org/10.1038/s41467-022-29288-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960874/
https://www.ncbi.nlm.nih.gov/pubmed/35347138
http://dx.doi.org/10.1038/s41467-022-29288-3

Ejemplares similares